Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway

European Journal of Cancer

Volumn 47, Issue 7, 2011, Pages 1115-1124

  Yue, Pan ^a   Gao, Zu Hua ^b   Xue, Xia ^a   Cui, Shu Xiang ^c   Zhao, Cui Rong ^a   Yuan, Yi ^a   Yin, Zhe ^d   Inagaki, Yoshinori ^e   Kokudo, Norihiro ^e   Tang, Wei ^a,e   Qu, Xian Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF CALGARY   (Canada)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Des carboxy prothrombin; ERK1 2 MAPK; Hepatocellular carcinoma; Matrix metalloproteinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DECARBOXYPROTHROMBIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAF PROTEIN; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LAMININ; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM METASTASIS; PHOSPHORYLATION; PROTEIN PRECURSORS; PROTEOGLYCANS; PROTHROMBIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79953720830     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.01.017     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 2000;6:565-8. (Pubitemid 30665270)
3. Gao ZH, Tretiakova MS, Liu WH, et al. Association of Ecadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol 2006;19:533-40.
4. Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002;97:425-31. (Pubitemid 34027799)
5. Yang C, Zeisberg M, Lively JC, et al. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 2003;63:8312-7. (Pubitemid 37549483)
6. Giglia JL, Antonia SJ, Berk LB, et al. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010;17:120-9.
7. Ajisaka H, Shimizu K, Miwa K. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma. J Surg Oncol 2003;84:89-93. (Pubitemid 37247914)
8. Otsuka M, Kato N, Shao RX, et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004;40:243-51. (Pubitemid 38868943)
9. Ma M, Qu XJ, Mu GY, et al. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gammacarboxy prothrombin. Chemotherapy 2009;55:28-35.
10. Murata K, Suzuki H, Okano H, et al. Hypoxia-induced desgamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010;36:161-70.
11. Inagaki Y, Tang W, Makuuchi M, et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int 2011;31:22-35.
12. Liebman HA. Isolation and characterization of a hepatomaassociated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989;49:6493-7. (Pubitemid 20008776)
13. Pang RW, Joh JW, Johnson PJ, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008;15:962-71.
14. Taketomi A, Sanefuji K, Soejima Y, et al. Impact of desgamma- carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-7.
15. Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-9. (Pubitemid 32105702)
16. Fujikawa T, Shiraha H, Ueda N, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007;282:8741-8. (Pubitemid 47093522)
17. Suzuki M, Shiraha H, Fujikawa T, et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005;280:6409-15. (Pubitemid 40341187)
18. Gao FJ, Cui SX, Chen MH, et al. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci 2008;83:815-20.
19. Wang SB, Cheng YN, Cui SX, et al. Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 2009;26:469-77.
20. Ueda N, Shiraha H, Fujikawa T, et al. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gammacarboxy prothrombin production in hepatocellular carcinoma cell lines. Mol Oncol 2008;2:241-9.
21. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40. (Pubitemid 39144478)
22. Baragi VM, Shaw BJ, Renkiewicz RR, et al. A versatile assay for gelatinases using succinylated gelatin. Matrix Biol 2000;19:267-73. (Pubitemid 30601759)
23. Mukherjee S, Roth MJ, Dawsey SM, et al. Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Transl Med 2010;8:91.
24. Song SY, Son HJ, Nam E, Rhee JC, Park C. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 2006;42:101-8. (Pubitemid 41814539)
25. Okutucu B, Dinçer A, Habib O, Zihnioglu F. Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 2007;70:709-11. (Pubitemid 47021223)
26. Meira DD, Nóbrega I, de Almeida VH, et al. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. Eur J Cancer 2009;45:1265-73.
27. Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M. Distribution of the heterogeneity of des-gammacarboxyprothrombin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:1545-52. (Pubitemid 43961109)
28. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009;16:2795-804.
29. Naraki T, Kohno N, Saito H, et al. Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated desgamma- carboxy prothrombin. Biochim Biophys Acta 2002;1586:287-98. (Pubitemid 34457923)
30. Desiderio MA. Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 2007;64:1341-54. (Pubitemid 46889234)
31. El-Obeid A, Hesselager G, Westermark B, Nistér M. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor. Biochem Biophys Res Commun 2002;90:349-58. (Pubitemid 34694506)
32. Qu XJ, Yang JL, Russell PJ, Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 2004;72:733-8. (Pubitemid 38900251)
33. Chen JS, Huang XH,Wang Q, et al. FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis 2010;27:71-82.
34. Chen JS, Wang Q, Fu XH, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009;39:177-86.
35. Allen DL, TeiteIbaum DH, Kurachi K. Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol 2003;284:C805-15.
36. Kargozaran H, Yuan SY, Breslin JW, et al. A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis 2007;24:495-502. (Pubitemid 47524807)
37. Lai K, Conway RM, Crouch R, Jager MJ, Madigan MC. Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res 2008;86:936-41.
38. Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 2002;19:275-82. (Pubitemid 34606752)
39. Liu S, Liang Y, Huang H, et al. ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor-beta1 stimulated glomerular podocytes. Cell Physiol Biochem 2005;16:207-16. (Pubitemid 41643020)
40. Lai KC, Huang AC, Hsu SC, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 2010;58:2935-42.
41. Suh SJ, Cho KJ, Moon TC, et al. 3,4,5-Trihydroxybenzaldehyde from Geum japonicum has dual inhibitory effect on matrix metalloproteinase 9; inhibition of gelatinolytic activity as well as MMP-9 expression in TNF-alpha induced HASMC. J Cell Biochem 2008;105:524-33.
42. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to Sphase transition. Oncogene 2007;26:3227-39. (Pubitemid 46763017)
43. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
44. Zhang S, Li Z, Wu X, et al. Methyl-3-indolylacetate inhibits cancer cell invasion by targeting the MEK1/2-ERK1/2 signaling pathway. Mol Cancer Ther 2006;5:3285-93. (Pubitemid 46092072)
45. Wang J, Zhang Z, Xu K, et al. Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway. Int J Cancer 2008;123:1311-7.
46. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84. (Pubitemid 47125967)
47. Wells A, Welsh JB, Lazar CS, et al. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 1990;247:962-4.